Clinical trial · Interventional
Neoadjuvant Immunotherapy in Early Stage Non-small-cell Lung Cancer Presenting as Synchronous Ground-glass Nodules
Neoadjuvant Anti-PD-1 Therapy in Early Stage Non-small-cell Lung Cancer Presenting as Synchronous Ground-glass Nodules: a Pilot Study
NCT04047186CI-TRIAL-00095679completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Neoadjuvant Immunotherapy in Early Stage Non-small-cell Lung Cancer Presenting as Synchronous Ground-glass Nodules: a pilot study
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Pulmonary Nodules | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Tislelizumab Injection | Drug | Tislelizumab | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- neoadjuvant PD-1 group
- description
- receiving neoadjuvant therapy of programmed death-1 (pd-1) immune checkpoint inhibitor
- interventionNames
- Drug: Tislelizumab Injection
Primary outcomes (1)
- measure
- Objective Response Rate
- timeFrame
- twelve weeks
Secondary outcomes (1)
- measure
- treatment-related adverse events
- timeFrame
- three months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * not less than two GGNs on chest CT * at least one lesion is diagnosed as NSCLC from biopsy pathology * no contraindication for surgery * ECOG score of 0 or 1 * no detectable evidence of distant metastasis Exclusion Criteria: * medical history of malignancy * pregnant or breeding period * severe organ failure (heart, liver, kidney, and lung) * high risk of cerebral-cardiovascular evens * infection out of control * received or receiving chemo- and radiotherapy * history of severe reaction due to allergy or hypersensitivity * severe mental disorder * currently been enrolled in other trials * autoimmune or chronic inflammatory disease
References
Publications (0)
Data not yet available
No reference posted for this study.